Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05236387 · ClinicalTrials.gov registry record
Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection
A clinical trial, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- 14
- Enrollment target
NCT05236387: Clinical Trial study, sponsored by Johns Hopkins University.
NCT05236387 is a clinical trial that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05236387 was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- 14 participants
- Enrollment target
Study Summary
The purpose of the present study is to evaluate the ability of 99mTc-TM to identify the clipped node after neoadjuvant chemotherapy (NAC) and to compare this percentage with historical national data. This study will also evaluate pain and discomfort after injection and pathological features of clipped nodes and any additional nodes removed.
Interventions
- DRUG 99m Tc-TM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-03-01 |
| Est. Completion | 2023-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05236387
The ClinicalTrials.gov registry entry for NCT05236387 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 99m Tc-TM is the first listed.
NCT05236387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05236387 about?
NCT05236387 is a clinical study titled "Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection". The purpose of the present study is to evaluate the ability of 99mTc-TM to identify the clipped node after neoadjuvant chemotherapy (NAC) and to compare this percentage with historical national data. This study will also evaluate pain and discomfort after injection and pathological features of clipp...
What is the current status of trial NCT05236387?
This trial is currently terminated. The enrollment target is 14 participants. The study started on 2022-03-01. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT05236387?
The interventions under investigation include: 99m Tc-TM (DRUG).
Who is sponsoring clinical trial NCT05236387?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.